Pluri (PLUR) Stock Price, News & Analysis

Company Overview

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Key Stats

• Today's Range: $4.69 to $5.29
• 50-Day Range: $3.96 to $5.79
• 52-Week Range: $3.33 to $7.13
• Volume: 18,924 shs
• Average Volume: 10,847 shs
• Market Capitalization: $38.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Pluri Stock Analysis - MarketRank™

Pluri scored higher than 41% of companies evaluated by MarketBeat, and ranked 660th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pluri has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Pluri has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pluri is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pluri is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pluri has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.67% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 4.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pluri does not currently pay a dividend.

Dividend Growth

Pluri does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.67% of the float of Pluri has been sold short.

Short Interest Ratio / Days to Cover

Pluri has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pluri has recently decreased by 4.28%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Pluri to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pluri insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.93% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 16.59% of the stock of Pluri is held by institutions.

PLUR Stock Analysis - Frequently Asked Questions

How have PLUR shares performed this year?

Pluri's stock was trading at $4.28 at the beginning of the year. Since then, PLUR shares have increased by 12.9% and is now trading at $4.83.

How were Pluri's earnings last quarter?

Pluri Inc. (NASDAQ:PLUR) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.94) earnings per share (EPS) for the quarter. The business had revenue of $0.43 million for the quarter. Pluri had a negative trailing twelve-month return on equity of 4,191.91% and a negative net margin of 2,563.29%.

When did Pluri's stock split?

Pluri's stock reverse split on Monday, April 1st 2024.The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Pluri?

Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pluri own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pluri investors own include Digital Turbine (APPS), Lightning eMotors (ZEV), Archer Aviation (ACHR), ChargePoint (CHPT) and Canoo (GOEV).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/08/2025
• Next Earnings (Estimated): 9/17/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PLUR
• CIK: 1158780
• Web: pluri-biotech.com
• Phone: 972747108600
• Fax: 972-74-710-8787
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pluri: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +148.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.89 million
• Net Margins: -2,563.29%
• Pretax Margin: -1,789.02%
• Return on Equity: -4,191.91%
• Return on Assets: -85.40%

Debt

• Debt-to-Equity Ratio: 51.65
• Current Ratio: 4.81
• Quick Ratio: 4.81

Sales & Book Value

• Annual Sales: $1.03 million
• Price / Sales: 36.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.00 per share
• Price / Book: 4.83

Miscellaneous

• Outstanding Shares: 7,871,000
• Free Float: 5,830,000
• Market Cap: $38.02 million
• Optionable: Optionable
• Beta: 0.76